Eargo to Present at BofA Securities 2021 Virtual Health Care Conference

SAN JOSE, Calif., April 19, 2021 (GLOBE NEWSWIRE) — Eargo, Inc. (Nasdaq: EAR), a medical device company on a mission to improve the quality of life for people with hearing loss, today announced it will present at the BofA Securities 2021 Virtual Health Care Conference via web cast. Christian Gormsen, Eargo’s President and Chief Executive Officer, is scheduled to present on Thursday, May 13th at 11:45 a.m. Eastern Time (8:45 a.m. Pacific Time).

The live web cast of Eargo’s presentation, along with accompanying slides, can be accessed at www.eargo.com and will be available for replay for 90 days following the live event.  

About Eargo

Eargo is a medical device company dedicated to improving the quality of life of people with hearing loss. Our innovative product and go-to-market approach address the major challenges of traditional hearing aid adoption, including social stigma, accessibility and cost. We believe our Eargo hearing aids are the first and only virtually invisible, rechargeable, completely-in-canal, FDA registered, exempt Class I or Class 2 devices for the treatment of hearing loss. Our differentiated, consumer-first solution empowers consumers to take control of their hearing. Consumers can purchase online or over the phone and get personalized and convenient consultation and support from licensed hearing professionals via phone, text, email or video chat. The Eargo solution is offered to consumers at approximately half the cost of competing hearing aids purchased through traditional channels in the United States.

The company’s 4th generation product, the Eargo Neo HiFi, was launched in January 2020 and features improved capabilities across audio fidelity and bandwidth. The Eargo Neo HiFi is available for purchase here.

Related Links
http://eargo.com

Investor Contact

Nick Laudico
Vice President of Investor Relations
[email protected]

Media Contact

Brad Sheets
[email protected]



ViewRay Announces Conference Call for First Quarter 2021 Financial Results to be Held After Market on May 6, 2021

PR Newswire

CLEVELAND, April 19, 2021 /PRNewswire/ — ViewRay, Inc. (Nasdaq: VRAY) announced today details relating to the release of its first quarter 2021 financial results.

ViewRay will hold a conference call to discuss results on Thursday, May 6, 2021 at 4:30 p.m. ET / 1:30 p.m. PT. The dial-in numbers are (888) 771-4371 for domestic callers and (847) 585-4405 for international callers. The confirmation number is 50150605. A live webcast of the conference call will be available on the investor relations page of ViewRay’s corporate website at http://investors.viewray.com/events-and-presentations/upcoming-events.

After the live webcast, a replay will remain available online on the investor relations page of ViewRay’s website, under “Financial Events and Webinars”, for 14 days following the call. In addition, a telephonic replay of the call will be available until May 13, 2021. The replay dial-in numbers are (855) 859-2056 for domestic callers and (404) 537-3406 for international callers. Please use the conference ID number 8484107.

About ViewRay®
ViewRay, Inc. (Nasdaq: VRAY), designs, manufactures, and markets the MRIdian® MR-Guided Radiation Therapy System. MRIdian is built upon a proprietary high-definition MR imaging system designed from the ground up to address the unique challenges and clinical workflow for advanced radiation oncology. Unlike MR systems used in diagnostic radiology, MRIdian’s high-definition MR was purpose-built to address specific challenges, including beam distortion, skin toxicity, and other concerns that potentially may arise when high magnetic fields interact with radiation beams. ViewRay and MRIdian are registered trademarks of ViewRay, Inc.

Forward-Looking Statements
This press release contains forward-looking statements within the meaning of Section 27A of the Private Securities Litigation Reform Act. Statements in this press release that are not purely historical are forward-looking statements. Such forward-looking statements include, among other things, the rate of new orders, upgrades, and installations, ViewRay’s expectations for 2021 and beyond and ViewRay’s conference calls to discuss its quarterly results.  Actual results could differ from those projected in any forward-looking statements due to numerous factors. Such factors include, among others, the ability to commercialize MRIdian Linac System, demand for ViewRay’s products, the ability to convert backlog into revenue, the timing of delivery of ViewRay’s products, the timing, length, and severity of the recent COVID-19 (coronavirus) pandemic, including its impacts across our businesses on demand, operations and our global supply chains, the results and other uncertainties associated with clinical trials, the ability to raise the additional funding needed to continue to pursue ViewRay’s business and product development plans, the inherent uncertainties associated with developing new products or technologies, competition in the industry in which ViewRay operates, and overall market conditions. For a further description of the risks and uncertainties that could cause actual results to differ from those expressed in these forward-looking statements, as well as risks relating to ViewRay’s business in general, see ViewRay’s current and future reports filed with the Securities and Exchange Commission, including its Annual Report on Form 10-K for the fiscal year ended December 31, 2020 and its Quarterly Reports on Form 10-Q, as updated periodically with the company’s other filings with the SEC. These forward-looking statements are made as of the date of this press release, and ViewRay assumes no obligation to update the forward-looking statements, or to update the reasons why actual results could differ from those projected in the forward-looking statements, except as required by law.

Cision View original content:http://www.prnewswire.com/news-releases/viewray-announces-conference-call-for-first-quarter-2021-financial-results-to-be-held-after-market-on-may-6-2021-301271845.html

SOURCE ViewRay, Inc.

Gulf Island Announces Sale of Shipyard Division Assets and Long-Term Contracts

HOUSTON, April 19, 2021 (GLOBE NEWSWIRE) — Gulf Island Fabrication, Inc. (“Gulf Island” or the “Company”) (NASDAQ: GIFI) today announced it has sold the assets and certain long-term vessel construction contracts of the Shipyard Division to Bollinger Shipyards, L.L.C. (“Bollinger Shipyards”) for approximately $28.6 million. Net cash proceeds resulting from the transaction are anticipated to be approximately $15 million after payment of retained working capital liabilities associated with the divested construction contracts and transaction costs and adjustments to account for changes in working capital from December 31, 2020 through the closing date. The net cash proceeds are expected to be used to fund net working capital liabilities associated with retained construction contracts and other Shipyard Division liabilities and the wind down of the Shipyard Division operations.

TRANSACTION RATIONALE


  • Transforms Gulf Island into a more focused, specialty fabrication business.
    Positions the Company for profitable growth in existing and new higher-margin markets.

  • Improves risk profile.
    Removes future risks associated with existing, long-term contracts that represent ~90% of the Company’s current backlog that extends through 2024.

  • Strengthens liquidity.
    Reduces the Company’s bonding, letters of credit and working capital requirements and is expected to lessen quarterly working capital fluctuations.

“This is a transformational transaction for Gulf Island, as it will enable us to accelerate our strategic priorities by significantly de-risking our business and positioning us to pursue new, higher-margin opportunities within our Fabrication & Services Division. We are well-positioned given the strategic initiatives implemented over the past year and we are excited by the opportunities for profitable growth that lay ahead,” said Richard Heo, Gulf Island’s President and Chief Executive Officer.

“I would like to thank our Shipyard team for their relentless commitment to quality and safety, while delivering on our obligations to our customers. We believe this divestiture is in the best interest of all our stakeholders, including our shareholders, employees and customers,” continued Heo.

“This transaction further supports our key strategic priorities of improving our financial strength and pursuing growth opportunities. As we focus on diversifying into new end markets with our Fabrication & Services Division, we will continue to deliver high-quality fabrication solutions to an expanded base of customers,” concluded Heo.

TRANSACTION OVERVIEW

The transaction includes the Shipyard Division property and assets in Houma, Louisiana, including all four of the Division’s drydocks. In addition, the transaction includes the long-term contracts and all related obligations for the construction of three research vessels for Oregon State University and five towing, salvage and rescue ships for the U.S. Navy. Excluded from the transaction are certain working capital liabilities associated with such divested construction contracts. Also excluded from the transaction are the contracts and related obligations for the construction of two forty-vehicle ferries for the North Carolina Department of Transportation, a seventy-vehicle ferry for the Texas Department of Transportation, and two multi-purpose service vessels for Hornbeck Offshore Services that are subject to dispute.

Gulf Island received $26.4 million at closing and will receive the remainder from Bollinger upon its collection of certain customer payments associated with the divested construction contracts. Net cash proceeds resulting from the transaction are anticipated to be approximately $15 million after payment of retained working capital liabilities associated with the divested construction contracts and transaction costs and adjustments to account for changes in working capital from December 31, 2020 through the closing date. The net cash proceeds are expected to be used to fund net working capital liabilities associated with the retained construction contracts and other Shipyard Division liabilities (which totaled approximately $13 million at December 31, 2020) and the wind down of the Shipyard Division operations, which is anticipated to occur by mid-2022. The Company anticipates recording a pre-tax loss of approximately $26 million to $28 million in connection with the transaction.

The Company will retain the $8.8 million payment received in the first quarter 2021 associated with the previously announced amendment to the U.S. Navy contracts.

TRANSACTION UPDATE CONFERENCE CALL

Gulf Island will hold a conference call on Tuesday, April 20, 2021 at 7:30 a.m. Central Time (8:30 a.m. Eastern Time) to discuss the transaction. The call will be available by webcast and can be accessed on Gulf Island’s website at www.gulfisland.com. Participants may also join the call by dialing 1.800.437.2398 and requesting the “Gulf Island” conference call. A replay of the webcast will be available on the Company’s website for seven days after the call.

ADVISORS

Johnson Rice & Company, L.L.C. acted as financial advisor and Jones Walker LLP acted as legal advisor to Gulf Island.

ABOUT BOLLINGER SHIPYARDS

Bollinger Shipyards has a 75-year legacy as a leading designer and builder of high performance military patrol boats and salvage vessels, research vessels, ocean-going double hull barges, offshore oil field support vessels, tugboats, rigs, lift boats, inland waterways push boats, barges, and other steel and aluminum products from its new construction shipyards as part of the U. S. industrial base. Bollinger has 11 shipyards, all strategically located throughout Louisiana with direct access to the Gulf of Mexico, Mississippi River and the Intracoastal Waterway. Bollinger is the largest vessel repair company in the Gulf of Mexico region.

ABOUT GULF ISLAND

Gulf Island is a leading fabricator of complex steel structures and modules and provider of project management, hookup, commissioning, repair, maintenance and civil construction services to the industrial and energy sectors. The Company’s customers include U.S. and, to a lesser extent, international energy producers; refining, petrochemical, LNG, industrial and power operators; and EPC companies. The Company is headquartered in Houston, Texas and its operating facilities are located in Houma, Louisiana.

CAUTIONARY NOTE ON FORWARD-LOOKING STATEMENTS

This Release contains forward-looking statements in which the Company discusses its potential future performance. Forward-looking statements, within the meaning of the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995, are all statements other than statements of historical facts, such as projections or expectations relating to diversification and entry into new end markets, improvement of risk profile, oil and gas prices, operating cash flows, capital expenditures and liquidity. The words “anticipates,” “may,” “can,” “plans,” “believes,” “estimates,” “expects,” “projects,” “targets,” “intends,” “likely,” “will,” “should,” “to be,” “potential” and any similar expressions are intended to identify those assertions as forward-looking statements.

The Company cautions readers that forward-looking statements are not guarantees of future performance and actual results may differ materially from those anticipated, projected or assumed in the forward-looking statements. Important factors that can cause its actual results to differ materially from those anticipated in the forward-looking statements include: the duration and scope of, and uncertainties associated with, the ongoing global pandemic caused by COVID-19 and the corresponding weakened demand for, and volatility of prices of, oil and the impact thereof on its business and the global economy, which are evolving and beyond its control; the potential forgiveness of any portion of the PPP Loan; its ability to secure new project awards, including fabrication projects for refining, petrochemical, LNG and industrial facilities and offshore wind developments; the Company’s ability to improve project execution; the cyclical nature of the oil and gas industry; competition; consolidation of its customers; timing and award of new contracts; reliance on significant customers; financial ability and credit worthiness of its customers; nature of its contract terms; competitive pricing and cost overruns on its projects; adjustments to previously reported profits or losses under the percentage-of-completion method; weather conditions; changes in backlog estimates; suspension or termination of projects; its ability to raise additional capital; its ability to amend or obtain new debt financing or credit facilities on favorable terms; its ability to generate sufficient cash flow; its ability to sell certain assets; any future asset impairments; utilization of facilities or closure or consolidation of facilities; customer or subcontractor disputes; its ability to resolve the dispute with a customer relating to the purported terminations of contracts to build two multi-purpose service vessels; operating dangers and limits on insurance coverage; barriers to entry into new lines of business; its ability to employ skilled workers; loss of key personnel; performance of subcontractors and dependence on suppliers; changes in trade policies of the U.S. and other countries; compliance with regulatory and environmental laws; lack of navigability of canals and rivers; systems and information technology interruption or failure and data security breaches; performance of partners in any future joint ventures and other strategic alliances; shareholder activism; focus on environmental, social and governance factors by institutional investors; and other factors described in Item 1A “Risk Factors” in the Company’s 2020 Annual Report as may be updated by subsequent filings with the SEC.

Investors are cautioned that many of the assumptions upon which the Company’s forward-looking statements are based are likely to change after the forward-looking statements are made, which it cannot control. Further, the Company may make changes to its business plans that could affect its results. The Company cautions investors that it does not intend to update forward-looking statements more frequently than quarterly notwithstanding any changes in its assumptions, changes in business plans, actual experience or other changes, and undertakes no obligation to update any forward-looking statements.

COMPANY INFORMATION

Richard W. Heo Westley S. Stockton
Chief Executive Officer Chief Financial Officer
713.714.6100 713.714.6100



CDK Global to Announce Third Quarter Fiscal 2021 Financial Results on May 6, 2021

HOFFMAN ESTATES, Ill., April 19, 2021 (GLOBE NEWSWIRE) — CDK Global, Inc. (Nasdaq: CDK), a leading retail automotive technology company, is scheduled to release its financial results for the fiscal third quarter ended March 31, 2021 after the closing of the Nasdaq market on Thursday, May 6, 2021.  

CDK will also be hosting a conference call at 4:00 p.m. CT on May 6, 2021 to discuss the results for the period. Brian Krzanich, chief executive officer, Joe Tautges, chief operating officer, Eric Guerin, chief financial officer, and Julie Schlueter, investor relations director, will be participating on the call.

Investors and interested participants are invited to listen to the conference call via live webcast, which can be accessed through the CDK Investor Relations home page, investors.cdkglobal.com. A supplemental slide presentation will be available approximately 30 minutes before the webcast on the CDK Investor Relations home page. A replay of the webcast will be available on the Events & Presentations section of the CDK Investor Relations home page.

About CDK Global, Inc.

CDK Global (Nasdaq: CDK) is a leading provider of integrated data and technology solutions to the automotive, heavy truck, recreation, and heavy equipment industries. Focused on enabling end-to-end, omnichannel retail commerce through open, agnostic technology, CDK Global provides solutions to dealers and original equipment manufacturers, serving nearly 15,000 retail locations in North America. CDK solutions connect people with technology by automating and integrating all parts of the dealership and buying process, including the acquisition, sale, financing, insuring, parts supply, repair and maintenance of vehicles. Visit cdkglobal.com

Investor Relations Contact:
[email protected]
847.485.4643



EXL Announces Retirement of Pavan Bagai as President and Chief Operating Officer

NEW YORK, April 19, 2021 (GLOBE NEWSWIRE) — EXL (NASDAQ: EXLS), a leading Operations Management and Analytics company, today announced that Pavan Bagai, President and Chief Operating Officer, will retire from the company effective as of October 1, 2021. Mr. Bagai’s responsibilities will be transitioned in an orderly manner to other members of EXL’s executive team over the course of the next several months.

Rohit Kapoor, Vice Chairman and Chief Executive Officer, said, “Pavan has been an architect of EXL as well as a mentor and friend of many within the company, including myself. He has been a great partner for me in building the organization into what it is today. Pavan’s career with EXL mirrors the company’s own growth. His leadership established the foundation of our operations management business, his guidance helped develop the Analytics business, and it is his insight that has enabled our shift to digital. In addition to guiding EXL to success, Pavan has been instrumental in navigating the company through every challenge it has faced, including most recently the COVID-19 pandemic. Above all, nurturing the ‘soul of EXL’ was always on Pavan’s mind, and he will leave an indelible mark on the organization and each of us. I am happy that Pavan will now be able to devote more time to his other passions. All of us at EXL will miss him, and we wish the best for him.” 

“On behalf of the Board and all of EXL, we thank Pavan for his 19 years of leadership and enormous contributions to the company,” commented Garen Staglin, Chairman of the Board. “Pavan’s dedication to our values, our customers, and our employees has inspired us all. We extend our sincere gratitude for his many years of service to EXL.”

Mr. Bagai said, “The decision to retire from EXL was not an easy one for me.  For nearly two decades the growth of our company and its people has been my prime motivator and I am extremely proud of what we have accomplished together.  My journey has been exciting, enjoyable and fulfilling.  It has been a pleasure working with Rohit, the rest of the leadership team, and indeed all the employees of EXL.  I leave knowing the company is the strongest it has ever been and stands well-positioned for the digital future.  I look forward to watching its continued success.”

About EXL

EXL (NASDAQ: EXLS) is a leading operations management and analytics company that helps our clients build and grow sustainable businesses. By orchestrating our domain expertise, data, analytics and digital technology, we look deeper to design and manage agile, customer-centric operating models to improve global operations, drive profitability, enhance customer satisfaction, increase data-driven insights, and manage risk and compliance. Headquartered in New York, EXL has approximately 31,900 professionals in locations throughout the United States, the United Kingdom, Europe, India, the Philippines, Colombia, Canada, Australia and South Africa. EXL serves customers in multiple industries including insurance, healthcare, banking and financial services, utilities, travel, transportation and logistics, media and retail, among others. For more information, visit www.exlservice.com.

Cautionary Statement Regarding Forward-Looking Statements

This press release contains forward-looking statements. You should not place undue reliance on those statements because they are subject to numerous uncertainties and factors relating to EXL’s operations and business environment, all of which are difficult to predict and many of which are beyond EXL’s control. Forward-looking statements include information concerning EXL’s possible or assumed future results of operations, including descriptions of its business strategy. These statements may include words such as “may,” “will,” “should,” “believe,” “expect,” “anticipate,” “intend,” “plan,” “estimate” or similar expressions. These statements are based on assumptions that we have made in light of management’s experience in the industry as well as its perceptions of historical trends, current conditions, expected future developments and other factors it believes are appropriate under the circumstances. You should understand that these statements are not guarantees of performance or results. They involve known and unknown risks, uncertainties and assumptions. Although EXL believes that these forward-looking statements are based on reasonable assumptions, you should be aware that many factors could affect EXL’s actual financial results or results of operations and could cause actual results to differ materially from those in the forward-looking statements. These factors are discussed in more detail in EXL’s filings with the Securities and Exchange Commission, including EXL’s Annual Report on Form 10-K. These risks could cause actual results to differ materially from those implied by forward-looking statements in this release. You should keep in mind that any forward-looking statement made herein, or elsewhere, speaks only as of the date on which it is made. New risks and uncertainties come up from time to time, and it is impossible to predict these events or how they may affect EXL. EXL has no obligation to update any forward-looking statements after the date hereof, except as required by federal securities laws.

Media Contact:

Michael Sherrill
Vice President Marketing
646-419-0778
[email protected]

Investor contact:

Steven N. Barlow
Vice President Investor Relations
917-596-7684
[email protected]



Allakos Appoints Baird Radford as Chief Financial Officer

REDWOOD CITY, Calif., April 19, 2021 (GLOBE NEWSWIRE) — Allakos Inc. (the “Company” or “Allakos”) (Nasdaq: ALLK), a biotechnology company developing lirentelimab (AK002) for the treatment of eosinophil and mast cell-related diseases, today announced that Baird Radford has been appointed Chief Financial Officer. As CFO, Mr. Radford will lead Allakos’ finance organization while working with the Company’s leadership team to drive its strategic initiatives and operating principles.

Mr. Radford has over 25 years of finance and leadership experience at public companies in multiple industries and various stages of growth. Prior to joining Allakos, Mr. Radford served as Senior Vice President of Finance at Aimmune Therapeutics where he was responsible for all aspects of strategic and operational finance activities supporting the launch of its first approved product, including financial planning, controllership, tax and treasury functions. Prior to working at Aimmune Therapeutics, he served as the Chief Financial Officer at HeartFlow and held senior finance positions at Intuitive Surgical, eBay and PricewaterhouseCoopers. Mr. Radford received his Bachelor of Business Administration from Ohio University.

“We are extremely pleased to have Baird join the Allakos team–he is a proven executive who has shaped and led successful teams. Baird brings broad experience and a track record of success at commercial-stage companies as we position Allakos for growth and potential commercialization of our first product candidate,” said Robert Alexander, PhD, chief executive officer of Allakos. “We look forward to leveraging Baird’s expertise as we enter the next critical phase of our growth.”

“With lirentelimab in a Phase 3 pivotal study, this is an exciting time to be joining Allakos,” said Mr. Radford. “I am honored to be part of the Allakos team and look forward to helping the company achieve its strategic objectives and financial goals as we work together to address the need for safe and effective therapies for eosinophil and mast cell-related diseases.”

About Allakos

Allakos is a clinical stage biotechnology company developing antibodies that target immunomodulatory receptors present on immune effector cells involved in allergic, inflammatory, and proliferative diseases. The Company’s lead antibody, lirentelimab (AK002), is being evaluated in a Phase 3 study in eosinophilic gastritis (EG) and/or eosinophilic duodenitis (EoD) and a Phase 2/3 study in eosinophilic esophagitis (EoE). Lirentelimab targets Siglec-8, an inhibitory receptor selectively expressed on human mast cells and eosinophils. Inappropriately activated eosinophils and mast cells have been identified as key drivers in a number of severe diseases affecting the gastrointestinal tract, eyes, skin, lungs and other organs. Lirentelimab has been tested in multiple clinical studies. In these studies, lirentelimab eliminated blood and tissue eosinophils, inhibited mast cells and improved disease symptoms in patients with EG and/or EoD, EoE, mast cell gastrointestinal disease, severe allergic conjunctivitis, chronic urticaria and indolent systemic mastocytosis. For more information, please visit the Company’s website at www.allakos.com.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 as contained in Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Such forward-looking statements include, but are not limited to, Allakos’ progress and business plans, the expected timing of anticipated study results and plans relating to its future clinical trials. Such statements are subject to numerous important factors, risks and uncertainties that may cause actual events or results to differ materially from current expectations and beliefs, including but not limited to: Allakos’ stages of clinical drug development; Allakos’ ability to timely complete clinical trials for, and if approved, commercialize lirentelimab (AK002), its lead compound; Allakos’ ability to obtain required regulatory approvals for its product candidates; uncertainties related to the enrollment of patients in its clinical trials; Allakos’ ability to demonstrate sufficient safety and efficacy of its product candidates in its clinical trials; uncertainties related to the success of later-stage clinical trials, regardless of the outcomes of preclinical testing and early-stage trials; market acceptance of Allakos’ product candidates; uncertainties related to the projections of the size of patient populations suffering from the diseases Allakos is targeting; Allakos’ ability to advance additional product candidates beyond lirentelimab; Allakos’ ability to obtain additional capital to finance its operations; and other important risk factors set forth in Allakos’ most recent Annual Report on Form 10-K filed with the SEC on March 1, 2021, and future reports to be filed with the SEC. These documents contain and identify important factors that could cause the actual results for Allakos to differ materially from those contained in Allakos’ forward-looking statements. Any forward-looking statements contained in this press release speak only as of the date hereof, and Allakos specifically disclaims any obligation to update any forward-looking statement, except as required by law. These forward-looking statements should not be relied upon as representing Allakos’ views as of any date subsequent to the date of this press release.

Source: Allakos Inc.



Investor Contact:
Adam Tomasi, President & COO
[email protected]

Media Contact:
Denise Powell
[email protected]

Liberty Global Schedules Investor Call for First Quarter 2021 Results

Liberty Global Schedules Investor Call for First Quarter 2021 Results

DENVER, Colorado–(BUSINESS WIRE)–
Liberty Global plc (“Liberty Global” or the “Company”) (NASDAQ: LBTYA, LBTYB and LBTYK) today announced plans to release its first quarter 2021 results on Wednesday, May 5, 2021 after Nasdaq market close. You are invited to participate in its Investor Call, which will begin the following day at 09:00 a.m. (Eastern Time) on Thursday, May 6, 2021. During the call, management will discuss the Company’s results, and may provide forward-looking information. Please dial in using the information provided below at least 15 minutes prior to the start of the call.

Domestic

800-289-0459

Conference Passcode

609063

International

+1 720-543-0298

 

In addition to the dial-in teleconference, a summary investor presentation and listen-only webcast will be available within the Investor Relations section of www.libertyglobal.com. The webcast will be archived in the Investor Relations section of the Company’s website for at least 75 days.

ABOUT LIBERTY GLOBAL

Liberty Global (NASDAQ: LBTYA, LBTYB and LBTYK) is one of the world’s leading converged video, broadband and communications companies, with operations in seven European countries under the consumer brands Virgin Media, Telenet, UPC, the combined Sunrise UPC, as well as VodafoneZiggo, which is owned through a 50/50 joint venture. Our substantial scale and commitment to innovation enable us to invest in the infrastructure and digital platforms that empower our customers to make the most of the digital revolution.

Liberty Global delivers market-leading products through next-generation networks that connect customers subscribing to 49 million broadband, video, fixed and mobile telephony services across our brands. We also have significant investments in ITV, All3Media, CANAL+ Polska, LionsGate, the Formula E racing series and several regional sports networks.

For more information, please visit www.libertyglobal.com.

Investor Relations:

Max Adkins +44 20 8483 6336

Stefan Halters +44 20 8483 6211

Steve Carroll +1 303 784 4505

Corporate Communications:

Molly Bruce +1 303 220 4202

Matt Beake +44 20 8483 6428

KEYWORDS: Colorado United States North America

INDUSTRY KEYWORDS: Networks Internet Mobile/Wireless Technology Telecommunications

MEDIA:

Logo
Logo

Eargo to Report First Quarter 2021 Financial Results on May 12, 2021

SAN JOSE, Calif., April 19, 2021 (GLOBE NEWSWIRE) — Eargo, Inc. (Nasdaq: EAR), a medical device company on a mission to improve the quality of life of people with hearing loss, today announced it will release financial results for the first quarter 2021 after market close on May 12, 2021. On the same day, Eargo will host a conference call and webcast at 2:00 p.m. Pacific Time (5:00 p.m. Eastern Time) to discuss its financial results and recent highlights.

Interested parties may access the live call via telephone by dialing (833) 649-1234 for domestic callers or (914) 987-7293 for international callers, using conference ID: 3971939. The live webinar of the call may also be accessed by visiting the Events and Presentations section of Eargo’s website at ir.eargo.com. A replay of the webinar will be available shortly after the conclusion of the call and will be archived on Eargo’s website for one year.

About Eargo

Eargo is a medical device company dedicated to improving the quality of life of people with hearing loss. Our innovative product and go-to-market approach address the major challenges of traditional hearing aid adoption, including social stigma, accessibility and cost. We believe our Eargo hearing aids are the first and only virtually invisible, rechargeable, completely-in-canal, FDA regulated, exempt Class I or Class II devices for the treatment of hearing loss. Our differentiated, consumer-first solution empowers consumers to take control of their hearing. Consumers can purchase online or over the phone and get personalized and convenient consultation and support from licensed hearing professionals via phone, text, email or video chat. The Eargo solution is offered to consumers at approximately half the cost of competing hearing aids purchased through traditional channels in the United States.

The company’s 4th generation product, the Eargo Neo HiFi, was launched in January 2020 and features improved capabilities across audio fidelity and bandwidth. The Eargo Neo HiFi is available for purchase here.

Related Links
http://eargo.com

Investor Contact

Nick Laudico
Vice President of Investor Relations
[email protected]

Media Contact

Brad Sheets
[email protected]



PrairieSky Announces 2021 First Quarter Results

CALGARY, Alberta, April 19, 2021 (GLOBE NEWSWIRE) —

PrairieSky Royalty Ltd. (“PrairieSky” or the “Company”) (TSX: PSK) is pleased to announce its first quarter (“Q1 2021“) operating and financial results for the period ended March 31, 2021.

First Quarter 2021 Highlights:
  Total revenues of $59.5 million increased 27% over Q4 2020 and 13% over Q1 2020 and was comprised of royalty production revenues of $56.7 million and other revenues of $2.8 million.
  Funds from Operations of $48.8 million ($0.22 per common share basic and diluted) were up 19% from Q4 2020 and 5% from Q1 2020.
  Royalty production averaged 19,380 BOE per day (50% liquids), a modest increase from Q4 2020 as the negative impact of cold weather freeze-offs on natural gas volumes were largely offset by incremental royalty production volumes from the Deep Basin Acquisition which closed in late February 2021.
  PrairieSky closed its previously announced royalty acquisition for cash consideration of $45.0 million, before adjustments, consolidating a significant fee mineral title, royalty, and seismic position in Western Canada (the “Deep Basin Acquisition”).
  Declared a first quarter dividend of $14.5 million ($0.065 per common share), representing a payout ratio of 30%, with remaining cash flow allocated to funding the Deep Basin Acquisition.
     

PRESIDENT’S MESSAGE

PrairieSky’s Q1 2021 results demonstrate the resiliency of our high margin business model with quarter over quarter increases in revenue, funds from operations and production. In late February 2021, PrairieSky closed the previously announced Deep Basin Acquisition. The acquired assets consist of approximately 640,000 net acres of royalty interest lands in Western Canada, including a 170,000 acre fee mineral title position with multizonal leasing, exploration and development potential; approximately 650 BOE per day of production (56% natural gas, 33% NGL, 11% oil); and ownership of approximately 3,200 square kilometres of 3D seismic and 3,100 kilometres of 2D seismic covering the acquired assets and PrairieSky’s existing fee mineral title acreage. Given the timing of closing the Deep Basin Acquisition, the Q1 2021 results described herein include contribution from the acquired assets for approximately one month.

PrairieSky generated funds from operations of $48.8 million during Q1 2021, a 19% increase over Q4 2020 and a 5% increase over Q1 2020. The increase in funds from operations over prior quarters was due primarily to the strength of West Texas Intermediate (“WTI”) and AECO benchmark pricing demonstrating the advantage of PrairieSky’s unhedged leverage to commodity prices. During the quarter, PrairieSky declared an increased quarterly dividend of $14.5 million, with remaining funds from operations of $34.3 million allocated to partially funding the previously announced Deep Basin Acquisition.

Total Q1 2021 royalty production revenue of $56.7 million was 30% above Q4 2020 royalty production revenue of $43.6 million and 15% above Q1 2020 royalty production revenue of $49.1 million. Royalty production revenue was generated from total royalty production volumes of 19,380 BOE per day which increased modestly from Q4 2020 royalty production volumes of 19,281 BOE per day but was down 13% from Q1 2020 royalty production volumes of 22,160 BOE per day as a result of a material decrease in field activity throughout 2020. A further breakdown of royalty revenue and production is as follows:

  • Oil royalty revenue totaled $36.5 million in Q1 2021, a 30% increase over Q4 2020 due primarily to stronger average WTI benchmark pricing which offset wider light and heavy oil differentials and a stronger Canadian dollar. Q1 2021 oil royalty production volumes of 7,278 barrels per day were in line with Q4 2020 as new wells brought on production in the quarter and minor contributions from the Deep Basin Acquisition more than offset declines. While Q1 2021 oil production was down 15% compared to Q1 2020, the strength of WTI benchmark pricing and narrowed light and heavy oil differentials drove the strong increase in Q1 2021 revenues and funds from operations compared to Q1 2020.
  • Natural gas royalty production volumes averaged 57.6 MMcf per day and generated $12.7 million of royalty revenue in the quarter. The 27% increase in revenue over Q4 2020 was a result of stronger AECO and Station 2 benchmark pricing and modest Deep Basin Acquisition volumes, which more than offset the negative revenue impact from production freeze-offs due to extreme cold temperatures throughout Western Canada in Q1 2021. Natural gas royalty revenue increased 40% over Q1 2020 revenue as improved benchmark pricing offset the impacts of production declines due to lower activity levels throughout 2020.
  • Natural gas liquids (“NGL”) volumes of 2,502 barrels per day increased 9% over Q4 2020 with production from new wells on stream and modest volumes from the Deep Basin Acquisition. NGL royalty revenue totaled $7.5 million, up 34% from Q4 2020 due to strong benchmark pricing. NGL royalty production volumes were down 15% as compared to Q1 2020 but strong benchmark pricing resulted in a 7% increase in NGL royalty revenue compared to Q1 2020.

Q1 2021 exploration and development activity was up from Q4 2020 but remained below Q1 2020 levels prior to the onset of the COVID-19 pandemic. There were 100 wells spud (86% oil) on PrairieSky lands during Q1 2021. Activity was weighted towards our GORR acreage with 65 wells, an additional 20 wells spud on Fee Lands and 15 wells spud in units. Oil activity was focused on the Viking play with 46 wells, the Clearwater with 13 wells, and the Cardium with 8 wells, with additional Bakken, Duvernay, Mannville, Mannville heavy oil and Mississippian wells spud in the quarter. There were 14 natural gas wells spud in Q1 2021, which included 9 Montney wells, 3 Spirit River wells and 2 Mannville wells. PrairieSky’s average royalty rate for Q1 2021 was 4.4%, which included a large number of unit wells in areas under waterflood that have a lower net royalty interest but provide royalties on a larger area of land.

Other revenue totalled $2.8 million in Q1 2021, comprised of $0.7 million of lease rentals, $0.7 million in other income and $1.4 million in bonus consideration. During the quarter, PrairieSky entered into 33 new leases with 29 different counterparties on both oil and natural gas plays across Alberta and Saskatchewan. Compliance recoveries totaled $0.8 million as staff continued their focus on ensuring timely and accurate royalty payments.

Cash administrative expenses totaled $5.7 million or $3.27 per BOE in the quarter, down 19% from Q1 2020 cash administrative expenses of $7.0 million or $3.47 per BOE. Cash administrative expenses are generally higher in the first quarter of the year when share-based compensation vests and is paid. In Q1 2021, share-based compensation payouts totaled $0.7 million for all staff and management, a 59% reduction from Q1 2020 share-based compensation payouts of $1.7 million, down materially year over year as a result of stock price performance and the impacts of COVID-19.

PrairieSky intends to apply to the Toronto Stock Exchange (“TSX”) to renew its NCIB for an additional one-year period. Subject to regulatory approval, PrairieSky intends to apply to purchase up to a maximum of 15,221,196 common shares of its currently issued and outstanding common shares over a period of twelve months. As of April 19, 2021, PrairieSky had 223,300,000 common shares issued and outstanding and 152,211,964 common shares issued and outstanding after excluding common shares beneficially owned by directors and executive officers of PrairieSky and persons who beneficially own or exercise control or direction over more than 10% of the issued and outstanding common shares of PrairieSky (the “Public Float”). The actual number of common shares that may be purchased will be determined by PrairieSky based on its assessment of capital allocation priorities. Any common shares that are purchased under the NCIB will be cancelled upon their purchase by PrairieSky. Management believes a normal course issuer bid provides an opportunity to use excess cash resources to reduce PrairieSky’s share count over time and represents an investment in PrairieSky’s high quality asset base and enhances value for shareholders.

Our virtual investor day will be held on May 18, 2021, when we will release our 2021 Playbook and our annual Responsibility Report. Our annual Responsibility Report will include an independent third-party verification of Net Zero GHG emissions (Scope 1 and 2) in 2020, verification of other key performance indicators and incremental Task Force on Climate-related Financial Disclosures (“TCFD”) and Sustainability Accounting Standards Board (“SASB”) disclosures. We expect both of these documents to highlight the unique attributes of our long duration, high margin business model, and our commitment to best practices in governance, social responsibility and environmental stewardship. Information for our investor day will be available on our website at www.prairiesky.com.  

We continue to prioritize the health and safety of our employees and the community and are following the advice of public health officials related to COVID-19. Substantially all of our dedicated team of professionals are working away from the office at this time, as we continue to execute on our strategy. I would like to thank our staff for their continued efforts and our shareholders for their support. Please contact Pam Kazeil, our Chief Financial Officer, at 587-293-4089 or myself at 587-293-4005 with any questions.

Andrew Phillips, President & CEO

FINANCIAL AND OPERATIONAL INFORMATION

The following table summarizes select operational and financial information of the Company for the periods noted. All dollar amounts are stated in Canadian dollars unless otherwise noted.

A full version of PrairieSky’s MD&A and unaudited interim condensed consolidated financial statements and notes thereto for the fiscal period ended March 31, 2021 is available on SEDAR at www.sedar.com and PrairieSky’s website at www.prairiesky.com

  Three months ended
  March 31, December 31, March 31,
(millions, except per share data or as otherwise noted)   2021     2020     2020  
FINANCIAL      
Revenues $                 59.5   $ 47.0   $ 52.7  
                   
Funds from Operations $                 48.8   $ 41.1   $ 46.5  
Per Share – basic and diluted(1) $                 0.22   $ 0.18   $ 0.20  
                   
Net Earnings $                 18.4   $ 14.1   $ 8.6  
Per Share – basic and diluted(1) $                 0.08   $ 0.06   $ 0.04  
                   
Dividends declared(2) $                 14.5   $ 13.4   $ 45.4  
Per Share $                 0.0650   $ 0.0600   $ 0.1950  
                   
Acquisitions, including non-cash consideration $                 45.6   $ 2.7   $ 0.5  
Working Capital (Deficiency) at period end $                 (57.2 ) $ (42.0 ) $ (5.2 )
Common share repurchases $                 –   $   $ 5.0  
                   
Shares Outstanding                  
Shares Outstanding at period end                   223.3     223.3     232.6  
Weighted average – basic                   223.3     223.3     233.0  
Weighted average – diluted                   223.7     223.8     233.4  
                   
OPERATIONAL                  
Royalty Production Volumes                  
Crude Oil (bbls/d)                   7,278     7,313     8,582  
NGL (bbls/d)                   2,502     2,285     2,945  
Natural Gas (MMcf/d)                   57.6     58.1     63.8  
Royalty Production (BOE/d)(3)                   19,380     19,281     22,160  
                   
Realized Pricing                  
Crude Oil ($/bbl) $                 55.71   $ 41.59   $ 42.30  
NGL ($/bbl)                   33.18     26.44     26.10  
Natural Gas ($/Mcf)                   2.45     1.87     1.57  
Total ($/BOE)(3) $                 32.51   $ 24.58   $ 24.35  
       
Operating Netback per BOE
(4)
$                 28.67   $ 22.10   $ 20.24  
Funds from Operations per BOE $                 27.98   $ 23.17   $ 23.06  
                   
Oil Price Benchmarks                  
Western Texas Intermediate (WTI) (US$/bbl) $                 57.86   $ 42.66   $ 46.17  
Edmonton Light Sweet ($/bbl) $                 66.60   $ 50.24   $ 51.44  
Western Canadian Select (WCS) crude oil                  
differential to WTI (US$/bbl) $                 (12.47 ) $ (9.30 ) $ (20.53 )
                   
Foreign Exchange Rate (US$/CAD$)                   0.7899     0.7694     0.7450  
                   
Natural Gas Price Benchmarks                  
AECO monthly index ($/Mcf) $                 2.93   $ 2.76   $ 2.14  
AECO daily index ($/Mcf) $                 3.15   $ 2.64   $ 2.03  
(1)     Net Earnings and Funds from Operations per Common Share are calculated using the weighted average number of basic and diluted common shares outstanding.
(2)     A dividend of $0.065 per common share was declared on March 9, 2021. The dividend was paid on April 15, 2021 to shareholders of record as at March 31, 2021.
(3)    See “Conversions of Natural Gas to BOE”.
(4)    Operating Netback per BOE is defined under the Non-GAAP Measures section in the MD&A.
 

CONFERENCE CALL DETAILS

A conference call to discuss the results will be held for the investment community on Tuesday, April 20, 2021 beginning at 6:30 a.m. MDT (8:30 a.m. EDT). To participate in the conference call, approximately 10 minutes prior to the conference call, please dial:

  (844) 657-2668 (toll free in North America)
  (612) 979-9882 (International)
  Conference ID: 8688297

VIRTUAL ANNUAL GENERAL MEETING

PrairieSky’s virtual annual general meeting of holders of common shares scheduled for Tuesday, April 20, 2021 at 9:30 a.m. (MDT). The virtual meeting will be conducted via live audio webcast at https://web.lumiagm.com/255695029. Shareholders will have an opportunity to participate at the annual general meeting online regardless of their geographic location. Below is some additional information on attending the virtual meeting. Further details are provided on our website at www.prairiesky.com/investors

Registered shareholders and duly appointed proxyholders will be able to listen to the virtual meeting, ask questions and vote online, all in real time, provided they are connected to the Internet and properly follow the instructions contained on the website. Non-registered (beneficial) shareholders who have not duly appointed themselves as proxyholders may still attend the virtual meeting as guests. Guests will be able to listen to the meeting but will not be able to vote at the meeting or ask questions.

  • https://web.lumiagm.com/255695029 in your web browser.

  • Password: prairie2021 (case sensitive).
  • If you have voting rights, select “Login” and follow the instructions.
  • If you do not have voting rights, select “Guest” and fill in the form.

We recommend that you log in to the webcast at least one hour before the time of the virtual meeting. PrairieSky encourages all shareholders to participate in the virtual annual general meeting.

NORMAL COURSE ISSUER BID

PrairieSky will apply to extend its NCIB for an additional one-year period. Under the renewed NCIB, and subject to prior approval of the TSX, PrairieSky intends to repurchase up to 15,221,196 common shares over a 12-month period. The NCIB has been approved by the Company’s board of directors; however, it is subject to acceptance by the TSX and, if accepted, will be made in accordance with the applicable rules and policies of the TSX and applicable securities laws. Under the NCIB, common shares may be repurchased in open market transactions on the TSX, and/or other Canadian exchanges or alternative trading systems. The price that PrairieSky will pay for common shares in open market transactions will be the market price at the time of purchase. Common shares acquired under the NCIB will be cancelled.

PrairieSky will file a Notice of Intention to Make a NCIB to purchase and cancel up to 10% of the public float. The 10% limit would be set based on the issued and outstanding shares as at April 30, 2021, after excluding common shares beneficially owned by directors and executive officers of PrairieSky and persons who beneficially own or exercise control or direction over more than 10% of the issued and outstanding common shares of PrairieSky, which for illustrative purposes would be 152,211,964 common shares as of April 19, 2021. The actual number of common shares that may be purchased, and the timing of any such purchases, will be determined by PrairieSky based on based on its assessment of capital allocation priorities. The NCIB is expected to commence shortly after regulatory approvals are obtained and upon expiry of the current program on May 18, 2021. Common shares may be repurchased under the program over a period of up to one year. As of March 31, 2021, PrairieSky has purchased and cancelled an aggregate of 9.1 million common shares at a weighted average price per share of $9.22 under a normal course issuer bid that commenced on May 19, 2020 and runs to May 18, 2021. Since instituting the normal course issuer bid in 2016 to March 31, 2021, PrairieSky has purchased and cancelled an aggregate of 15.0 million common shares at a weighted average price per share of $14.90.

PrairieSky will be entering into an automatic purchase plan with its broker in order to facilitate purchases of its common shares. The automatic purchase plan allows for purchases by the Company of its common shares at any time, including, without limitation, when the Company would ordinarily not be permitted to make purchases due to regulatory restriction or self-imposed blackout periods. Purchases will be made by PrairieSky’s broker based upon the parameters prescribed by the TSX and the terms of the parties’ written agreement.

PrairieSky believes renewing the NCIB as part of its capital management strategy is in the best interests of the Company and represents an attractive opportunity to use cash resources to reduce PrairieSky’s share count over time and thereby enhance the value of the shares held by remaining shareholders. The Board currently intends to evaluate the NCIB, and the level of purchases thereunder, on an annual basis in conjunction with PrairieSky’s annual financial results. The next regularly scheduled review will be in February 2022.

While PrairieSky currently intends to only purchase up to 15,221,196 common shares over the next 12 months, the Company’s board of directors may consider, from time to time, applying to the TSX to increase the amount of NCIB purchases. Decisions regarding increases to the NCIB will be based on market conditions, share price, best use of funds from operations, and other factors including other options to expand our portfolio of royalty assets.

2021 INVESTOR DAY

PrairieSky will be hosting a virtual investor day on May 18, 2021, where members of PrairieSky’s management team will present details on the Company’s crude oil and natural gas plays. Due to COVID-19 restrictions, the investor day will be a live webcast starting at 9:30 a.m. EDT. Interested parties may participate in the webcast available through PrairieSky’s investor center at www.prairiesky.com. A copy of materials will also be available on PrairieSky’s website at www.prairiesky.com. The webcast will be archived and accessible for replay after the event.

FORWARD-LOOKING STATEMENTS

This press release includes certain statements regarding PrairieSky’s future plans and operations and contains forward-looking statements that we believe allow readers to better understand our business and prospects. The use of any of the words “expect”, “anticipate”, “continue”, “estimate”, “objective”, “ongoing”, “may”, “will”, “project”, “should”, “believe”, “plans”, “intends”, “strategy”” and similar expressions are intended to identify forward-looking information or statements. Forward-looking statements contained in this press release include estimates regarding our expectations with respect to PrairieSky’s business and growth strategy, future growth from PrairieSky’s existing royalty asset portfolio, the quality of PrairieSky’s existing royalty asset portfolio, improvement in the business in the near, medium and long term, the impacts and potential future impacts of the COVID-19 pandemic, future collections from compliance activities and future activity on PrairieSky’s lands, the application of PrairieSky to renew the NCIB, and the timing thereof, the number of common shares which may be purchased under the NCIB in the future and the factors in determining the timing and quantum of such purchases, PrairieSky’s belief that repurchasing such common shares under the NCIB is a good investment of PrairieSky’s resources, and the timing and content of PrairieSky’s annual Responsibility Report including the independent third party verification of certain key performance data.

With respect to forward-looking statements contained in this press release, we have made several assumptions including those described in detail in our MD&A and the Annual Information Form for the year ended December 31, 2020. Readers and investors are cautioned that the assumptions used in the preparation of such forward-looking information and statements, although considered reasonable at the time of preparation, may prove to be imprecise and, as such, undue reliance should not be placed on forward-looking statements. Our actual results, performance, or achievements could differ materially from those expressed in, or implied by, these forward-looking statements. We can give no assurance that any of the events anticipated will transpire or occur, or if any of them do, what benefits we will derive from them.

By their nature, forward-looking statements are subject to numerous risks and uncertainties, some of which are beyond our control, including the impact of general economic conditions, industry conditions, volatility of commodity prices, lack of pipeline capacity, currency fluctuations, imprecision of reserve estimates, competitive factors impacting royalty rates, environmental risks, taxation, regulation, changes in tax or other legislation, competition from other industry participants, the lack of availability of qualified personnel or management, stock market volatility, political and geopolitical instability and our ability to access sufficient capital from internal and external sources. In addition, PrairieSky is subject to numerous risks and uncertainties in relation to acquisitions. These risks and uncertainties include risks relating to the potential for disputes to arise with counterparties, and limited ability to recover indemnification under certain agreements. The foregoing and other risks are described in more detail in PrairieSky’s MD&A, and the Annual Information Form for the year ended December 31, 2020 under the headings “Risk Management” and “Risk Factors”, respectively, each of which is available at www.sedar.com and PrairieSky’s website at www.prairiesky.com

Further, any forward-looking statement is made only as of the date of this press release, and PrairieSky undertakes no obligation to update or revise any forward-looking statement or statements to reflect events or circumstances after the date on which such statement is made or to reflect the occurrence of unanticipated events, except as required by applicable securities laws. New factors emerge from time to time, and it is not possible for PrairieSky to predict all of these factors or to assess in advance the impact of each such factor on PrairieSky’s business or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in any forward-looking statements. The forward-looking information contained in this document is expressly qualified by this cautionary statement.

CONVERSIONS OF NATURAL GAS TO BOE

To provide a single unit of production for analytical purposes, natural gas production and reserves volumes are converted mathematically to equivalent barrels of oil (BOE). PrairieSky uses the industry-accepted standard conversion of six thousand cubic feet of natural gas to one barrel of oil (6 Mcf = 1 bbl). The 6:1 BOE ratio is based on an energy equivalency conversion method primarily applicable at the burner tip. It does not represent a value equivalency at the wellhead and is not based on either energy content or current prices. While the BOE ratio is useful for comparative measures and observing trends, it does not accurately reflect individual product values and might be misleading, particularly if used in isolation. As well, given that the value ratio, based on the current price of crude oil to natural gas, is significantly different from the 6:1 energy equivalency ratio, using a 6:1 conversion ratio may be misleading as an indication of value.

NON-GAAP MEASURES

Certain measures in this document do not have any standardized meaning as prescribed by International Financial Reporting Standards (“IFRS”) and, therefore, are considered non-GAAP measures. These measures may not be comparable to similar measures presented by other issuers. These measures are commonly used in the crude oil and natural gas industry and by PrairieSky to provide potential investors with additional information regarding the Company’s liquidity and its ability to generate funds to conduct its business. Non-GAAP measures include operating netback per BOE, payout ratio and cash administrative expenses per BOE. Management’s use of these measures is discussed further below. Further information can be found in the Non-GAAP Measures section of PrairieSky’s MD&A.

“Operating Netback per BOE” represents the cash margin for products sold on a BOE basis. Operating netback per BOE is calculated by dividing the operating netback (royalty production revenues less production and mineral taxes and administrative expenses) by the average daily production volumes for the period. Operating netback per BOE is used to assess the cash generating and operating performance per unit of product sold and the comparability of the underlying performance between years. Operating netback per BOE measures are commonly used in the crude oil and natural gas industry to assess performance comparability.

“Payout Ratio” is calculated as dividends declared as a percentage of funds from operations. Payout ratio is used by dividend paying companies to assess dividend levels in relation to the funds generated and used in operating activities.

“Cash Administrative Expenses” represents administrative expenses excluding the volatility and fluctuations in share-based compensation expense for RSUs, PSUs, ODSUs and DSUs and stock options that were not settled in cash in the current period. Cash administrative expenses are calculated as total administrative expenses, adjusting for share-based compensation expense (recovery) in the period, plus any actual cash payments made under the RSU, PSU, ODSU or DSU plans. Management believes cash administrative expenses are a common benchmark used by investors when comparing companies to evaluate operating performance. 

“Cash Administrative Expenses per BOE” represents cash administrative expenses on a BOE basis. Cash administrative expenses per BOE is calculated by dividing cash administrative expenses by the average daily production volumes for the period. Cash administrative expenses per BOE assists management and investors in evaluating operating performance on a comparable basis.

Cash Administrative Expenses

The following table presents the computation of Cash Administrative Expenses:

   
  Three months ended
  March 31,


  December 31


  March 31,


(millions) 2021


  2020


  2020


Total Administrative Expenses $ 10.2   $ 4.9   $ 4.5
Share-Based Compensation Expense (Recovery)    (5.2)     (1.4)     0.8
Cash Payments Made – Share Unit Award Incentive Plan(1)     0.7     –       1.7
Cash Administrative Expenses $ 5.7   $ 3.5   $ 7.0
(1) See PrairieSky’s MD&A for details on its share-based compensation plans.
 

ABOUT PRAIRIESKY ROYALTY LTD.

PrairieSky is a royalty company, generating royalty production revenues as petroleum and natural gas are produced from its properties. PrairieSky has a diverse portfolio of properties that have a long history of generating funds from operations and that represent the largest and most consolidated independently-owned fee simple mineral title position in Canada. PrairieSky’s common shares trade on the Toronto Stock Exchange under the symbol PSK.

FOR FURTHER INFORMATION PLEASE CONTACT:

Andrew Phillips
President & Chief Executive Officer
PrairieSky Royalty Ltd.
(587) 293-4005

Pamela Kazeil
Vice President, Finance & Chief Financial Officer
PrairieSky Royalty Ltd.
(587) 293-4089

Investor Relations
(587) 293-4000
www.prairiesky.com  

PDF available: http://ml.globenewswire.com/Resource/Download/c9743487-e7d0-487c-92fe-00081f6ce661 



Incyte and MorphoSys Announce First Patient Dosed in Phase 3 inMIND Study Evaluating the Addition of Tafasitamab to Lenalidomide and Rituximab in Relapsed or Refractory Follicular or Marginal Zone Lymphoma

Incyte and MorphoSys Announce First Patient Dosed in Phase 3 inMIND Study Evaluating the Addition of Tafasitamab to Lenalidomide and Rituximab in Relapsed or Refractory Follicular or Marginal Zone Lymphoma

WILMINGTON, Del. & PLANEGG, Germany & MUNICH–(BUSINESS WIRE)–
Incyte (Nasdaq:INCY) and MorphoSys AG (FSE: MOR; Prime Standard Segment; MDAX & TecDAX; NASDAQ:MOR) today announced the first patient has been dosed in the placebo-controlled Phase 3 inMIND study evaluating the efficacy and safety of tafasitamab or placebo in combination with lenalidomide and rituximab in patients with relapsed or refractory follicular lymphoma (FL) or marginal zone lymphoma (MZL).

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210419005587/en/

“Despite improvements in treatment for patients with relapsed or refractory FL and MZL, there continues to be a significant medical need for additional therapies with improved outcomes,” said Peter Langmuir, M.D., Group Vice President, Oncology Targeted Therapeutics, Incyte. “We are pleased to have initiated the inMIND study as we seek meaningful, new options for patients with relapsed or refractory FL or MZL.”

FL and MZL are the most common indolent, or slow growing, forms of B-Cell non-Hodgkin lymphomas (NHLs). FL and MZL account for approximately 20-25% and 7% of adult NHL cases, respectively.1 There are limited treatment options for the more than 17,000 new cases of relapsed or refractory FL treated every year in the United States, Europe and Japan.2

“We are looking forward to building on previous, exploratory data in FL, and the results seen with tafasitamab and lenalidomide in relapsed or refractory diffuse large B-cell lymphoma, to evaluate the potential benefit of adding tafasitamab to the current lenalidomide and rituximab combination regimen in patients with indolent lymphomas,” said Mike Akimov, M.D., Ph.D., Head of Global Drug Development, MorphoSys.

On January 7, 2021, the U.S. Food and Drug Administration granted orphan drug designation to tafasitamab for the treatment of FL.

About inMIND

inMIND (NCT04680052), a global, double-blind, placebo-controlled, randomized Phase 3 study, is evaluating whether tafasitamab and lenalidomide as an add-on to rituximab provides improved clinical benefit compared with lenalidomide alone as an add-on to rituximab in patients with relapsed or refractory follicular lymphoma (FL) Grade 1 to 3a or relapsed or refractory nodal, splenic or extranodal marginal zone lymphoma (MZL). The study is expected to enroll over 600 adult (age ≥18 years) patients with relapsed or refractory FL or MZL.

The primary endpoint of the study is progression-free survival (PFS) in the FL population, and the key secondary endpoints are PFS and overall survival (OS) in the overall population as well as positron emission tomography complete response (PET-CR) at the end of treatment (EOT) in the FL population.

For more information about the study, please visit: https://clinicaltrials.gov/ct2/show/NCT04680052

About Tafasitamab

Tafasitamab is a humanized Fc-modified cytolytic CD19 targeting monoclonal antibody. In 2010, MorphoSys licensed exclusive worldwide rights to develop and commercialize tafasitamab from Xencor, Inc. Tafasitamab incorporates an XmAb® engineered Fc domain, which mediates B-cell lysis through apoptosis and immune effector mechanism including antibody-dependent cell-mediated cytotoxicity (ADCC) and antibody-dependent cellular phagocytosis (ADCP).

Monjuvi® (tafasitamab-cxix) is approved by the U.S. Food and Drug Administration in combination with lenalidomide for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) not otherwise specified, including DLBCL arising from low grade lymphoma, and who are not eligible for autologous stem cell transplant (ASCT). This indication is approved under accelerated approval based on overall response rate. Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial(s).

In January 2020, MorphoSys and Incyte entered into a collaboration and licensing agreement to further develop and commercialize tafasitamab globally. Monjuvi® is being co-commercialized by Incyte and MorphoSys in the United States. Incyte has exclusive commercialization rights outside the United States.

A marketing authorization application (MAA) seeking the approval of tafasitamab in combination with lenalidomide in the EU has been validated by the European Medicines Agency (EMA) and is currently under review for the treatment of adult patients with relapsed or refractory DLBCL, including DLBCL arising from low grade lymphoma, who are not candidates for ASCT.

Tafasitamab is being clinically investigated as a therapeutic option in B-cell malignancies in a number of ongoing combination trials.

Monjuvi® is a registered trademark of MorphoSys AG.

XmAb® is a registered trademark of Xencor, Inc.

Important Safety Information

What are the possible side effects of MONJUVI?

MONJUVI may cause serious side effects, including:

  • Infusion reactions. Your healthcare provider will monitor you for infusion reactions during your infusion of MONJUVI. Tell your healthcare provider right away if you get chills, flushing, headache, or shortness of breath during an infusion of MONJUVI.
  • Low blood cell counts (platelets, red blood cells, and white blood cells). Low blood cell counts are common with MONJUVI, but can also be serious or severe. Your healthcare provider will monitor your blood counts during treatment with MONJUVI. Tell your healthcare provider right away if you get a fever of 100.4°F (38°C) or above, or any bruising or bleeding.
  • Infections. Serious infections, including infections that can cause death, have happened in people during treatments with MONJUVI and after the last dose. Tell your healthcare provider right away if you get a fever of 100.4°F (38°C) or above, or develop any signs and symptoms of an infection.

The most common side effects of MONJUVI include:

  • Feeling tired or weak
  • Diarrhea
  • Cough
  • Fever
  • Swelling of lower legs or hands
  • Respiratory tract infection
  • Decreased appetite

These are not all the possible side effects of MONJUVI.

Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.

Before you receive MONJUVI, tell your healthcare provider about all your medical conditions, including if you:

  • Have an active infection or have had one recently.
  • Are pregnant or plan to become pregnant. MONJUVI may harm your unborn baby. You should not become pregnant during treatment with MONJUVI. Do not receive treatment with MONJUVI in combination with lenalidomide if you are pregnant because lenalidomide can cause birth defects and death of your unborn baby.

    • You should use an effective method of birth control (contraception) during treatment and for at least 3 months after your final dose of MONJUVI.
    • Tell your healthcare provider right away if you become pregnant or think that you may be pregnant during treatment with MONJUVI.
  • Are breastfeeding or plan to breastfeed. It is not known if MONJUVI passes into your breastmilk. Do not breastfeed during treatment for at least 3 months after your last dose of MONJUVI.

You should also read the lenalidomide Medication Guide for important information about pregnancy, contraception, and blood and sperm donation.

Tell your healthcare provider about all the medications you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements.

Please see the full Prescribing Information for Monjuvi, including Patient Information, for additional Important Safety Information.

About Incyte

Incyte is a Wilmington, Delaware-based, global biopharmaceutical company focused on finding solutions for serious unmet medical needs through the discovery, development and commercialization of proprietary therapeutics. For additional information on Incyte, please visit Incyte.com and follow @Incyte.

About MorphoSys

MorphoSys (FSE & NASDAQ: MOR) is a commercial-stage biopharmaceutical company dedicated to the discovery, development and commercialization of innovative therapies for patients suffering from cancer and autoimmune diseases. Based on its leading expertise in antibody, protein and peptide technologies, MorphoSys, together with its partners, has developed and contributed to the development of more than 100 product candidates, of which 27 are currently in clinical development. In 2017, Tremfya®, developed by Janssen Research & Development, LLC and marketed by Janssen Biotech, Inc., for the treatment of plaque psoriasis, became the first drug based on MorphoSys’ antibody technology to receive regulatory approval. In July 2020, the U.S. Food and Drug Administration (FDA) granted accelerated approval of MorphoSys’ proprietary product Monjuvi® (tafasitamab-cxix) in combination with lenalidomide in patients with a certain type of lymphoma. Headquartered near Munich, Germany, the MorphoSys group, including the fully owned U.S. subsidiary MorphoSys US Inc., has more than 600 employees. More information at www.morphosys.com or www.morphosys-us.com.

Monjuvi® is a registered trademark of MorphoSys AG.

Tremfya® is a registered trademark of Janssen Biotech, Inc.

Incyte Forward-Looking Statements

Except for the historical information set forth herein, the matters set forth in this press release, including statements regarding Incyte’s ongoing clinical development program for tafasitamab in patients with relapsed/refractory follicular lymphoma (FL) or marginal zone lymphoma (MZL), the enrollment, design, and timing and results of the clinical trial program, including the inMIND study, and whether tafasitamab will become an approved treatment option for patients with relapsed or refractory FL or relapsed or refractory MZL, contain predictions, estimates and other forward-looking statements.

These forward-looking statements are based on Incyte’s current expectations and subject to risks and uncertainties that may cause actual results to differ materially, including unanticipated developments in and risks related to: unanticipated delays; further research and development and the results of clinical trials possibly being unsuccessful or insufficient to meet applicable regulatory standards or warrant continued development; the ability to enroll sufficient numbers of subjects in clinical trials; determinations made by the FDA; Incyte’s dependence on its relationships with its collaboration partners; the efficacy or safety of Incyte’s products and the products of the Incyte’s collaboration partners; the acceptance of Incyte’s products and the products of Incyte’s collaboration partners in the marketplace; market competition; sales, marketing, manufacturing and distribution requirements; greater than expected expenses; expenses relating to litigation or strategic activities; and other risks detailed from time to time in Incyte’s reports filed with the Securities and Exchange Commission, including its Form 10-K for the year ended December 31, 2020. Incyte disclaims any intent or obligation to update these forward-looking statements.

MorphoSys Forward-Looking Statements

This communication contains certain forward-looking statements concerning the MorphoSys group of companies, including the expectations regarding Monjuvi’s ability to treat patients with relapsed or refractory diffuse large B-cell lymphoma, the further clinical development of tafasitamab-cxix, including ongoing confirmatory trials, additional interactions with regulatory authorities and expectations regarding future regulatory filings and possible additional approvals for tafasitamab-cxix as well as the commercial performance of Monjuvi. The words “anticipate,” “believe,” “estimate,” “expect,” “intend,” “may,” “plan,” “predict,” “project,” “would,” “could,” “potential,” “possible,” “hope” and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. The forward-looking statements contained herein represent the judgment of MorphoSys as of the date of this release and involve known and unknown risks and uncertainties, which might cause the actual results, financial condition and liquidity, performance or achievements of MorphoSys, or industry results, to be materially different from any historic or future results, financial conditions and liquidity, performance or achievements expressed or implied by such forward-looking statements. In addition, even if MorphoSys’ results, performance, financial condition and liquidity, and the development of the industry in which it operates are consistent with such forward-looking statements, they may not be predictive of results or developments in future periods. Among the factors that may result in differences are MorphoSys’ expectations regarding risks and uncertainties related to the impact of the COVID-19 pandemic to MorphoSys’ business, operations, strategy, goals and anticipated milestones, including its ongoing and planned research activities, ability to conduct ongoing and planned clinical trials, clinical supply of current or future drug candidates, commercial supply of current or future approved products, and launching, marketing and selling current or future approved products, the global collaboration and license agreement for tafasitamab, the further clinical development of tafasitamab, including ongoing confirmatory trials, and MorphoSys’ ability to obtain and maintain requisite regulatory approvals and to enroll patients in its planned clinical trials, additional interactions with regulatory authorities and expectations regarding future regulatory filings and possible additional approvals for tafasitamab-cxix as well as the commercial performance of Monjuvi, MorphoSys’ reliance on collaborations with third parties, estimating the commercial potential of its development programs and other risks indicated in the risk factors included in MorphoSys’ Annual Report on Form 20-F and other filings with the U.S. Securities and Exchange Commission. Given these uncertainties, the reader is advised not to place any undue reliance on such forward-looking statements. These forward-looking statements speak only as of the date of publication of this document. MorphoSys expressly disclaims any obligation to update any such forward-looking statements in this document to reflect any change in its expectations with regard thereto or any change in events, conditions or circumstances on which any such statement is based or that may affect the likelihood that actual results will differ from those set forth in the forward-looking statements, unless specifically required by law or regulation.


1 Swerdlow SH, Campo E, Pileri SA, et al. The 2016 revision of the World Health Organization classification of lymphoid neoplasms. Blood 2016;127:2375-2390.

2 Decision Resources Group. Non-Hodgkin’s Lymphoma and Chronic Lymphocytic Leukemia, Landscape & Forecast. 2020.

Incyte Contacts

Media:

Catalina Loveman

Executive Director, Public Affairs

Tel: +1 302 498 6171

[email protected]

Jenifer Antonacci

Senior Director, Public Affairs

Tel: +1 302 498 7036

[email protected]

Investors:

Christine Chiou

Senior Director, Investor Relations

Tel: +1 302 274 4773

[email protected]

MorphoSys Contacts

Media:

Thomas Biegi

Vice President

Tel.: +49 (0)89 / 89927 26079

[email protected]

Jeanette Bressi

Director, US Communications

Tel: +1 617-404-7816

[email protected]

Investors:

Dr. Julia Neugebauer

Senior Director

Tel: +49 (0)89 / 899 27 179

[email protected]

Myles Clouston

Senior Director

Tel: +1-857-772-0240

[email protected]

KEYWORDS: Germany Europe United States North America Delaware

INDUSTRY KEYWORDS: Biotechnology General Health Health Pharmaceutical Oncology

MEDIA:

Logo
Logo
Logo
Logo